{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Supine SBP Value < 90mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"2"}]}],"title":"Supine SBP Increase Change >= 30mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"}]}],"title":"Supine SBP Decrease Change >= 30mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Supine DBP Value < 50mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}]}],"title":"Supine SBP Increase Change >= 20mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"}]}],"title":"Supine DBP Decrease Change >= 20mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}]}],"title":"Supine Pulse Rate Value > 120mmHg"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"44"}],"units":"Participants"}],"description":"Vital signs criteria included: supine systolic blood pressure (SBP) \\<90 millimeters of mercury (mmHg), increase and decrease in change of more than or equal to (\\>=) 30mmHg; supine diastolic blood pressure (DBP) \\<50 mmHg, increase and decrease in change of \\>= 20mmHg; pulse rate \\<40 beats per minute (bpm) to \\>120 bpm. Only rows which included at least 1 participant in any reporting group with abnormality were reported in this outcome measure.","groups":[{"description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses).","id":"OG000","title":"Part A: Placebo"},{"description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG001","title":"Part A: Ponsegromab 100 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG002","title":"Part A: Ponsegromab 200 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG003","title":"Part A: Ponsegromab 400 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. Here, ''Overall Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Day 1 up to Week 12","title":"Part A: Number of Participants With Post-Baseline Vital Signs Meeting the Predefined Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}